A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

You may not qualify if:

• Participated in an interventional clinical trial or has used investigational devices within 28 days prior to first dose of study drug or received any following systemic anti-cancer treatments:
• cytotoxic chemotherapy, targeted therapy, immune checkpoint inhibitor within 4 weeks (such as PD-1 inhibitor, PD-L1 inhibitor, or CTLA-4 inhibitor);
• radiotherapy within 2 weeks (palliative radiotherapy is allowed at least 1 week before the study drug treatment).
• Toxicity and side effects (due to previous anticancer treatments) have not recovered to ≤ grade 1, unless such AE is not considered to pose safety risks (such as hair loss and neuropathy ≤ grade 2 caused by chemotherapy).
• Required use of corticosteroids for more than 7 consecutive days within 14 days prior to the first dose of study treatment (\> 10 mg daily prednisone equivalent for solid tumors; \> 20 mg daily prednisone equivalent for CTCL)
• Patients with active or history of or risk of autoimmune disease
• Major surgery (except biopsy) or unhealed wound within 4 weeks prior to first dose of study drug
• Any other current or previous malignancy within the past 2 years except a) adequately treated basal cell or squamous cell skin cancer, b) carcinoma in situ of the cervix, c) carcinoma in situ of the breast d) local prostate cancer after radical resection and/ or definitive radiotherapy with stable prostate specific antigen (PSA) levels for 1 years
• Has known active central nervous system (CNS) metastases
• History of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis, symptomatic interstitial lung disease or evidence of active pneumonia that is not considered appropriate by the investigator
• History of immunodeficiency (including HIV infection)
• Known active hepatitis B or C infection
• Patients with clinically significant cardiovascular diseases
• History of severe allergic reaction to the study drug or excipients used in the protocol
• Has had an allogeneic tissue/solid organ transplant or graft-versus-host disease